Join to access to all OVN content. Join for Free
Fierce Pharma Engage 2025 - RECAP
Fierce Pharma Engage 2025 medical affairs chatbot MSLMastery.com interdisciplinary interaction AI in medical affairs ChatGPT applications NPR-style podcasts conference takeaways medical affairs professionals artificial intelligence.

Fierce Pharma Engage 2025 - RECAP


Share This Article


Summary

In this episode, Tom Caravela and Patrina Pellett explore the highlights of the Fierce Pharma Engage 2025 conference. They discuss the conference's format, content, sessions, networking opportunities, and compare it to previous years. Keynote highlights and speaker impressions are shared, followed by a discussion on AI's future in the industry. The episode shares key conference takeaways and advice for medical affairs professionals.

Key Points

  • The launch of a medical affairs chatbot named Mira, trained on specialized content and accessible through MSLMastery.com, was highlighted as a significant innovation for the field.
  • The Fierce Pharma Engage conference featured a new format combining four different tracks—medical affairs, marketing, PR, and business development—allowing for increased interdisciplinary interaction among attendees.
  • The session on artificial intelligence in medical affairs, including live demos of ChatGPT applications and the creation of NPR-style podcasts from scientific papers, demonstrated practical AI use cases that resonated strongly with the audience.

Click for Source
Fierce Pharma Engage 2025, medical affairs chatbot, MSLMastery.com, interdisciplinary interaction, AI in medical affairs, ChatGPT applications, NPR-style podcasts, conference takeaways, medical affairs professionals, artificial intelligence.

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Empowering people to drive medical affairs performance with AI
Partner Avatar Envision Pharma Group

Empowering people to drive medical affairs performance with AI

Podcast
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How Medical Affairs Professionals Should Engage with Digital Opinion Leaders

Podcast
AI in Medical Affairs
Partner Avatar MSL Talk: Tom Caravela

AI in Medical Affairs

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Explore OVN